PSA Screening for Prostate Cancer: Guideline Summary

Introduction to Screening

The American College of Physicians recommends against screening in men under 50, over 69, or with life expectancy <10-15 years 2, 4, 5
The UK National Screening Committee recommends against systematic population screening 1, 4

PSA screening prevents approximately 1-2 prostate cancer deaths per 1,000 men screened over 13 years in men aged 55-69 years 3
The European ERSPC trial showed a 21% relative reduction in prostate cancer mortality, but this required screening 781 men and treating 27 patients to prevent one death 5
Overdiagnosis affects 29-44% of all PSA-detected cancers, meaning these men receive cancer diagnoses that would never have caused symptoms or death 3
For every 1 prostate cancer death prevented, 37 additional men receive unnecessary cancer diagnoses with exposure to all treatment harms but no benefit 3

For men aged 55-69 years, engage in structured shared decision-making before any testing, explaining the small potential benefit and common harms 1, 2, 3
For men aged 70+ years or with life expectancy <10 years, recommend against screening because harms clearly outweigh benefits in this population 1, 2, 3
For men under age 55 (average risk), do not offer screening as there is no evidence supporting benefit in this age group 1, 2, 5

Consider earlier screening discussions for African American men (start at age 45) and men with one first-degree relative diagnosed before age 65 (start at age 45) 8, 5
Apply the same shared decision-making framework as for average-risk men aged 55-69 8

The Canadian Task Force (2014) recommends against routine screening with a weak recommendation for ages 55-69 and strong recommendation against for all other ages 1, 4
The American Cancer Society (2016) supports screening discussions starting at age 50 for average-risk men, age 45 for high-risk men, and age 40 for very high-risk men 1, 2, 8
The USPSTF recommendation (2018) represents the evidence-based middle ground: shared decision-making for ages 55-69, recommend against for age 70+ 1

Determine eligibility: Age 55-69 with 10+ year life expectancy 3
Use structured discussion to explain benefits and harms, and assess patient preference 3
If screening is chosen, use biennial intervals (every 2 years) rather than annual screening to reduce harms while maintaining most benefits 7, 6